BB
BBIXF.US Bonus BioGroup Ltd
- Market cap
- USD 46.7M
- P/E
- -
- P/B
- 10.44x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BBIXF.US undervalued?
Graham numberThe Graham number of Bonus BioGroup Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bonus BioGroup Ltd fundamental analysis
No fundamental analysis for Bonus BioGroup Ltd yet.
Bonus BioGroup Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bonus BioGroup Ltd
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the …
Full company profileBonus BioGroup Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bonus BioGroup Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -1.14M | -1.34M | -2.14M | -1.33M | -1.61M | -4.10M | -3.37M | -2.95M | -2.51M | -2.74M | - |
| Operating Income | -16.0M | -20.1M | -18.5M | -20.9M | -19.4M | -64.7M | -37.0M | -29.8M | -27.8M | -22.5M | -23.2M |
| EBITDA | -15.4M | -20.0M | -18.2M | -20.7M | -18.4M | -88.0M | -35.1M | -27.0M | -25.0M | -19.8M | -20.5M |
| Net Income | -16.0M | -20.2M | -18.7M | -22.2M | -22.0M | -90.1M | -38.7M | -28.5M | -27.8M | -24.4M | -24.1M |
| EPS | -0.07 | -0.02 | -0.02 | -0.03 | -0.02 | -0.08 | -0.03 | -0.02 | -0.02 | -0.04 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 2.90M | 5.58M | 10.2M | 6.99M | 51.4M | 104M | 74.6M | 44.9M | 23.4M | 15.4M | 14.2M |
| Total Liabilities | 10.3M | 12.0M | 13.3M | 20.7M | 20.8M | 19.9M | 18.2M | 15.6M | 16.4M | 21.0M | 22.6M |
| Shareholders' Equity | -7.36M | -6.38M | -3.18M | -13.7M | 30.7M | 84.4M | 56.4M | 29.3M | 6.96M | -5.64M | -8.48M |
| Cash & Short-term Investments | 1.40M | 2.73M | 8.64M | 105K | 16.1M | 79.5M | 53.6M | 12.9M | 6.86M | 227K | 439K |
| Total Debt | - | - | - | 5.88M | 5.15M | 12.4M | 12.0M | 11.2M | 10.2M | 8.86M | 8.18M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.63M | -11.8M | -13.4M | -13.1M | -15.7M | -39.8M | -28.8M | -26.4M | -21.4M | -14.9M | -16.4M |
| Capital Expenditure | 191K | 269K | 341K | 187K | 254K | 5.81M | 6.39M | 824K | 342K | 11.9K | 60.0K |
| Free Cash Flow | -9.82M | -12.1M | -13.8M | -13.3M | -16.0M | -45.6M | -35.2M | -27.2M | -21.7M | -14.9M | -16.5M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -71.8% | -106.7% | -68.6% | -97.4% | -400.0% | - | - |
| ROA | -554.1% | -362.1% | -184.4% | -318.2% | -42.8% | -86.3% | -51.9% | -63.6% | -118.9% | -158.6% | -170.1% |
| Debt to Equity | - | - | - | - | 0.17x | 0.15x | 0.21x | 0.38x | 1.46x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bonus BioGroup Ltd dividends
Bonus BioGroup Ltd has not paid dividends in the last 9 fiscal years.
Who owns Bonus BioGroup Ltd
- Insiders 45.05%
- Institutions 0.00%
- Public & others 54.95%
- Shares outstanding 1.17B
- Free float 638M
Bonus BioGroup Ltd company profile
- Company name
- Bonus BioGroup Ltd
- Ticker
- BBIXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 42
- Fiscal year end
- December
- Address
- Matam Advanced Technology Park, Haifa, Israel, 3190501
- Phone
- 972 7 3206 7100
- Website
- bonus-bio.com
About Bonus BioGroup Ltd
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.
Bonus BioGroup Ltd management
6- Mr. Joseph Rauch M.B.A.Executive Chairman of the Board · born 1957
- Dr. Shai Meretzki Ph.D.Founder, CEO, President & Director · born 1969
- Ms. Meital Enbar CPAVice President of Finance · born 1979
- Dr. Dror Ben David Ph.D.Chief Operations Officer · born 1977
- Dr. Tomer Bronshtein Ph.D.Vice President of Innovation & Corporate Development
- Dr. Vered Kivity M.B.A., Ph.D.Head of Regulatory Affairs & VP of Clinical Affairs